Abcam (ABC) Hits New 12-Month High at $1,289.00

Shares of Abcam Plc (LON:ABC) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 1,289 ($18.07) and last traded at GBX 1,228 ($17.22), with a volume of 374057 shares changing hands. The stock had previously closed at GBX 1,260 ($17.67).

ABC has been the topic of a number of research analyst reports. Numis Securities raised Abcam to a “buy” rating and set a GBX 1,200 ($16.83) target price on the stock in a research report on Friday, January 5th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,240 ($17.39) target price on shares of Abcam in a research report on Friday, January 5th. Peel Hunt reissued a “hold” rating and issued a GBX 1,020 ($14.30) target price on shares of Abcam in a research report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 946 ($13.26) target price on shares of Abcam in a research report on Monday, January 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of GBX 1,009.33 ($14.15).

The firm has a market capitalization of $2,520.00 and a PE ratio of 5,847.62.

TRADEMARK VIOLATION WARNING: This piece was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://sportsperspectives.com/2018/02/08/abcam-abc-hits-new-12-month-high-at-1289-00.html.

Abcam Company Profile

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply